Correction to: Infection https://doi.org/10.1007/s15010-021-01709-3

On page 6 following the heading “Omadacycline”, the following items need clarification:

  • In the 2nd paragraph, comparing omadacycline (n = 388 patients) and moxifloxacin (n = 386 patients).

  • In the 2nd paragraph, the rates of adverse events given are those that corresponded to treatment discontinuation due to an adverse event.

  • In the 3rd paragraph, omadacycline had been tested in 316 patients, compared to linezolid in 311 patients.

  • In the 3rd paragraph, in the MITT, the early response rate was 84.8% vs. 85.5%, respectively.

  • In the 3rd paragraph, the rates of adverse events given are those that were considered treatment-related.

Table 1 (table updated),

  • omadacycline does not have EMA approval (indicated by an ‘X’).

  • omadacycline has activity against ESBL (indicated by a check mark) (Table 1).

Table 1 Summary of antibiotics in the pipeline and their spectrum of activities
Full size table

The original article has been corrected.